Amneal Pharmaceuticals - Class A (AMRX) closed at $21.38 on November 10, 2026, up 0.5% from the previous close, on volume of 2,008,864 shares (30-day average 4,182,518).
Data as of November 10, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 26, 2026 | 3 Leg Call/Put Combo Calendar | 18-Dec-2617.5 C|19-Mar-2720 C : 20 P | 3,000 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
Amneal Named BioSpace 2027 Best Place to Work, Ranking No.1 Among Large Employers
Globe Newswire (Tue, 10-Nov 4:02 PM ET)
Amneal Earnings Call Signals Strong Growth Ahead
TipRanks (Sun, 8-Nov 7:26 PM ET)
Amneal Reports Third Quarter 2026 Financial Results
Globe Newswire (Tue, 3-Nov 6:00 AM ET)
Amneal to Report Third Quarter 2026 Results on November 3, 2026
Globe Newswire (Thu, 8-Oct 8:00 AM ET)
Amneal Launches FDA-Approved Lanreotide, Targeting a $983 Million Reference Market
Market Chameleon (Mon, 21-Sep 7:15 AM ET)
Amneal Announces FDA Approval and Launch of Lanreotide Injection
Globe Newswire (Fri, 18-Sep 4:01 PM ET)
Business Wire (Wed, 19-Aug 8:00 AM ET)
AMRX to Join S&P SmallCap 600 Amid Index Shuffle: What the Move Means for Investors
Market Chameleon (Wed, 28-Jan 4:29 AM ET)
Amneal Targets Major Growth with Early Biosimilar Submission for $4.1B XOLAIR Market
Market Chameleon (Fri, 26-Sep 5:46 AM ET)
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Amneal Pharmaceuticals - Class A trades on the NASDAQ stock market under the symbol AMRX.
As of November 11, 2026, AMRX stock price climbed to $21.84 with 867,683 million shares trading.
AMRX has a beta of 0.68, meaning it tends to be less sensitive to market movements. AMRX has a correlation of 0.05 to the broad based SPY ETF.
AMRX has a market cap of $7.61 billion. This is considered a Mid Cap stock.
Last quarter Amneal Pharmaceuticals - Class A reported $863 million in Revenue and $.26 earnings per share. This beat revenue expectation by $45 million and exceeded earnings estimates by $.02.
In the last 3 years, AMRX traded as high as $22.01 and as low as $4.15.
The top ETF exchange traded funds that AMRX belongs to (by Net Assets): IJR, VTI, IWM, VB, VBR.
AMRX has outperformed the market in the last year with a price return of +90.2% while the SPY ETF gained +12.7%. AMRX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +22.1% and +1.9%, respectively, while the SPY returned -1.4% and -1.2%, respectively.
AMRX support price is $20.91 and resistance is $21.85 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AMRX shares will trade within this expected range on the day.
